Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
Purpose
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
Condition
- Covid19
Eligibility
- Eligible Ages
- Between 18 Years and 80 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of COVID-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours prior to informed consent - Males must be sterile, OR agree not to donate semen AND agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - Females must be unable to bear children, OR ensure that their male partner is incapable of fathering a child, OR, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - Females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - Females must have a negative pregnancy test at screening - Participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol
Exclusion Criteria
- Concomitant bacterial respiratory infection documented by respiratory culture. NOTE: Subjects on empirical antibiotic treatment for possible but unproven bacterial pneumonia, but who are positive for SARS-CoV-2, are allowed in the study. - Previous use of antiviral drugs that may be active against Covid-19. - Abnormal laboratory test results at screening: - Use of adrenocorticosteroids (except topical or inhaled preparations or oral preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers). NOTE: Treatment of study participants following institutional COVID-19 treatment policies or guidelines, including the use of immunomodulatory medications, is permitted. This excludes treatment with agents that have the potential for direct antiviral activity, including convalescent plasma and NO, and co-enrollment into other clinical studies that evaluate investigational agents for COVID-19. - Serious chronic disease (e.g., human immunodeficiency virus [HIV], cancer requiring chemotherapy within the preceding 6 months, and/or moderate or severe hepatic insufficiency). - Previously received camostat mesilate within the past 30 days. - Advanced kidney disease - Advanced liver disease - History of alcohol or drug abuse in the previous 6 months. - Psychiatric illness that is not well controlled (defined as stable on a regimen for more than one year). - Taken another investigational drug within the past 30 days. - Seemed by the Investigator to be ineligible for any reason.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Camostat mesilate |
Patients will receive camostat mesilate for 10 days in addition to standard of care treatment. |
|
|
Placebo Comparator Placebo |
Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment. |
|
Recruiting Locations
More Details
- NCT ID
- NCT04524663
- Status
- Completed
- Sponsor
- Stanford University